Antibody-Based Cancer Therapeutics at CIOC 2027

Antibody-based cancer therapeutics represent a promising frontier in cancer research, leveraging the body's own immune system to target and destroy cancer cells with remarkable precision. These therapies utilize monoclonal antibodies engineered to recognize specific proteins expressed on cancer cells, enabling targeted delivery of potent anti-cancer agents or triggering immune responses against tumors. By sparing healthy cells and minimizing side effects, antibody-based therapies offer a more targeted and personalized approach to cancer treatment. Key examples include immune checkpoint inhibitors like pembrolizumab and rituximab for certain lymphomas. Ongoing research continues to refine these therapies, exploring novel targets and combination strategies to enhance efficacy and broaden applicability across different cancer types, paving the way for more effective and less toxic treatments in the fight against cancer.